Articles tagged with Macular Degeneration
A Canadian study reveals that obesity reprograms immune system cells, making them destructive to the eye as it ages. The research sheds light on the molecular mechanism behind AMD and may lead to tailored treatments in the future.
Mount Sinai researchers discovered that age-related macular degeneration (AMD) may be caused by two distinct types of deposits in the retina: drusen and subretinal drusenoid deposits (SDDs). Early intervention with vitamin supplements can slow down drusen formation, while SDDs pose a greater threat to advanced AMD.
Scientists have created eye tissue using patient stem cells and 3D bioprinting, providing a model for studying the genesis of age-related macular degeneration. The printed tissue exhibited patterns of early AMD, including drusen deposits and progression to late dry stage AMD.
Researchers have identified a Vegf-Notch signaling system that enables Muller glial cells to regenerate retinal neurons in zebrafish. This discovery may help understand why the human retina does not regenerate and could inform treatments for blindness.
A pilot study found that nearly half of patients treated with aflibercept could safely stop eye injections without vision loss, while only 17% of those on bevacizumab were able to do so. The findings suggest that matching patients with the right therapy may reduce the need for lifelong treatment.
A new study from Mount Sinai Hospital finds a strong association between age-related macular degeneration and severe forms of heart disease, including heart failure, heart attacks, and stroke. The study highlights the importance of increased screening for eye disorders to diagnose undetected heart disease.
Researchers have discovered how a new class of drugs can inhibit the complement system, which causes damage to the body in some cases. These findings pave the way for further optimization of such inhibitors, potentially leading to novel therapeutic strategies for treating autoimmune diseases.
Researchers at Sanford Burnham Prebys have discovered the flexible structure of a key blood protein involved in macular degeneration and other age-related diseases. The study reveals how this protein adapts to changing pressure, leading to calcified plaque deposits characteristic of these conditions.
Researchers from Trinity College Dublin have developed a new gene therapy approach targeting mitochondrial function to treat dry AMD, a debilitating eye disease. The therapy has shown benefit in multiple models of the condition, offering hope for a potential treatment that could help millions globally.
Scientists reprogrammed stem cells to create models of diseased eye cells, analyzing DNA, RNA, and proteins to pinpoint genetic signatures. The study identified 439 molecular signatures associated with AMD, including potential new gene variants that target mitochondrial proteins.
A recent study found that patients vividly remember the way they were told they had their condition, which affects their perception of vision loss and interactions with others. Clinicians should consider empathetic communication when delivering bad news to minimize long-term psychological impact.
The new human cell line, ABC, was developed from retinal pigment epithelial cells and retains their properties, allowing for the study of events relevant to normal repair processes. The research may lead to discoveries in senescence gene programming, neuroprotection, and cellular replacement therapies for blinding eye diseases
A study found that patients with a specific form of age-related macular degeneration are at significant risk for cardiovascular disease and stroke. Researchers discovered a strong association between the disorder's subretinal drusenoid deposits and high-risk vascular diseases.
Researchers found a protein in eye fluid linked to disease progression in patients with wet age-related macular degeneration. Measuring its levels can accurately predict treatment needs, allowing for safe reduction or cessation of therapies.
Researchers have developed a new protocol for differentiating human embryonic stem cells into retinal pigment epithelial (RPE) cells, which can be used to treat age-related macular degeneration. The study shows that the protocol produces a pure population of RPE cells that can continue maturing after transplantation, paving the way for...
A new report confirms the benefits of supplements containing lutein and zeaxanthin for slowing age-related macular degeneration progression. The AREDS2 study found that these supplements reduced the risk of AMD progression by 26% compared to the original formula, which contained beta-carotene.
Researchers investigated the effects of treatment with exogenous Humanin G on inflammation markers in AMD and normal retinal cells. The study found reduced levels of inflammatory proteins in AMD plasma and treated cybrids, highlighting the positive effects of Humanin G.
A new study by the University of South Australia found that up to a quarter of people aged over 50 with undiagnosed visual problems like cataracts or AMD are misdiagnosed with mild cognitive impairment. Cognitive tests relying on vision-dependent tasks can skew results.
Researchers discovered that fusing Müller glia with adult stem cells can differentiate into ganglion cells, a type of neuron essential for vision. This finding brings hope for recovering the retina's regenerative capacity in humans.
Scientists identify a specialized zone in Muller glia cells called the citrullination bunker that sequesters damaged proteins, preserving vision. Chronic engagement of this process may lead to retinal degeneration, but inhibiting it could delay or prevent disease.
Researchers at MDI Biological Laboratory discovered that age-related chronic inflammation is caused by disruption of chromatin architecture. This leads to misexpression of genes lacking CpG islands, resulting in inflammation and loss of cellular function. The findings provide a unifying theory for the age-related degenerative diseases.
A study by Stanford researchers found that a thin chip and specially designed glasses can partially restore vision in macular degeneration patients, integrating their prosthetic central visual perception with the remaining natural peripheral vision. The treatment suggests restoring functional vision.
A comprehensive study investigates the metabolism of four drugs in rabbit eyes, revealing different enzyme profiles from liver metabolism. The findings provide valuable information for advancing ophthalmic drug development.
Researchers found that a third of patients with wet age-related macular degeneration can safely stop eye injection therapy without further vision loss. Patients who stopped treatment showed better visual acuity, gain of vision, and less fluid in their retina compared to those requiring continued injections.
A study published in Nutrients found that consuming a small serving of dried goji berries five times a week for 90 days increased lutein and zeaxanthin levels in healthy participants' eyes. This increase provides antioxidant protection and filters out harmful blue light, potentially delaying age-related vision loss.
Researchers developed a dish-based model that replicates the characteristics of dry age-related macular degeneration, allowing them to screen over 1,200 drugs for their ability to slow or halt disease progression. Two drugs, Aminocaproic acid and L745, showed promise in inhibiting key phenotypes associated with AMD.
Researchers have found that people with genetic risk factors for age-related macular degeneration (AMD) have thinner retinas and photoreceptors, even if they haven't yet lost their sight. This early detection could lead to earlier treatment and lifestyle changes to prevent vision loss.
The HyVIS project is a four-year European initiative that will develop bionic synapses for retinal prostheses, exploiting residual neuronal functionality to restore sensitivity to light. The approach involves plasmonic nanocannals and intelligent polymers to release neurotransmitters in response to light stimuli.
Researchers discovered that retinal pigment epithelium cells release exosomes containing normal proteins and those associated with drusen, a key AMD manifestation. This finding may lead to early diagnosis through biomarker detection in blood, tears, or saliva, potentially treating millions of Americans before geographic atrophy onset.
Researchers at the University of Colorado School of Medicine have been awarded a four-year grant to study systemic biomarkers of inflammation that signal the progression of age-related macular degeneration. The team aims to develop risk profiles for patients with intermediate AMD to predict rapid vision deterioration.
A study by Massachusetts General Hospital researchers has identified specific drugs that can selectively block the polarization of M2-type macrophages, which exacerbate diseases such as wet age-related macular degeneration. The findings suggest that these drugs could be repurposed for new therapies to influence disease outcomes.
Researchers at UVA Health System found that fluoxetine, an antidepressant commonly known as Prozac, shows promise against age-related macular degeneration. Patients taking fluoxetine were less likely to develop dry AMD, a condition affecting nearly 200 million people worldwide.
Researchers have discovered toxic DNA buildup in the eyes of patients with geographic atrophy, a devastating form of age-related macular degeneration. Common HIV drugs or safer alternatives, such as Kamuvudines, may block inflammation and protect against retinal cell death, offering new hope for treatment.
Researchers from the University of Bonn have found that reading ability is a crucial indicator of functional loss in people with geographic atrophy, a late form of age-related macular degeneration. Reading speed and performance are essential for measuring everyday functional impairment.
Researchers co-led by Jonathan L. Haines are conducting a comprehensive analysis of genetic data from over 100,000 people worldwide to better understand the condition. The study aims to uncover the genetic architecture of age-related macular degeneration and its impact on diverse populations.
Researchers at Duke University developed a robotic imaging tool that can automatically detect and scan patients' eyes for eye diseases, producing clear images in under 50 seconds. The system uses optical coherence tomography and is designed to be safe and accessible for optometrist offices, primary-care clinics, and emergency departments.
A study published in Nature Communications found that the process removing old light sensors is disrupted in progressive blindness, leading to age-related macular degeneration. The researchers identified mTORC1 as a key component involved in photoreceptor recycling and suggest potential treatments using drugs against mTORC1.
Researchers developed a novel medical device using octopus vision technology to assess macular pigment levels, enabling optometrists to provide preventative advice to patients. The technology can screen people from 5-95 years of age for low macular pigments, a strong risk factor for macular degeneration.
Researchers at the University of Rochester have developed a 3D lab model mimicking the human retina affected by age-related macular degeneration. The model combines patient-derived tissues with bioengineered synthetic materials, allowing for targeted drug therapies and potential individual treatments.
A team of researchers has developed a potential approach to overcome anti-VEGF resistance in patients with age-related macular degeneration. By combining apolipoprotein A-I binding protein (AIBP) with anti-VEGF, the strategy effectively suppresses choroidal neovascularization (CNV) and reduces drug resistance.
A new study suggests that exercise can reduce the development of macular degeneration by up to 45% in lab mice. The research also implies that regular physical activity may benefit other causes of vision loss, such as glaucoma and diabetic retinopathy.
Researchers have identified interleukin-4 as a key player in promoting harmful blood-vessel growth in age-related macular degeneration. Elevated levels of the protein were found in patients with AMD and mice with an AMD-like condition, highlighting its potential role as a target for new treatments.
A new Penn Medicine study found that missing a single ophthalmology appointment over a two-year period was associated with decreased visual acuity for patients with macular degeneration. Patients who attended more frequent visits had better visual outcomes, highlighting the importance of visit adherence for this patient population.
Scientists have discovered a potential way to halt blinding macular degeneration by targeting an enzyme called Dicer, which is lost with age and leads to damage in the retina. The approach uses gene therapy to restore the enzyme, offering a new treatment option for both dry and wet forms of AMD.
A University of Houston research team is exploring the connection between macular degeneration and retinitis pigmentosa by studying the protein peripherin2. By modulating ROM1 levels, they found a way to convert severe macular degeneration phenotypes into less severe retinitis pigmentosa phenotypes.
Researchers suggest a thermally induced fluid mixing approach could improve the delivery of anti-vascular endothelial growth factor agents to target tissue. This technique may reduce the amount of drug injected into the vitreous and increase effective treatment outcomes for patients with macular degeneration.
A degenerative eye condition called AMD is projected to affect 77 million Europeans by 2050, with the number of existing cases rising by 15% and new cases increasing by 75%. The estimated projections show that one in four older adults will have AMD, ranging from under 1 in 10 for those younger than 65 to over 27% of those over 75.
A new study from City, University of London suggests that patients diagnosed with dry AMD may experience considerable distress despite reasonable visual function. Effective communication with eye health professionals and timely information about the disease can alleviate anxiety and fear of going blind.
A study examining calcium intake found that higher intake was associated with a lower risk of progression to late AMD. However, the association between calcium intake and different stages of AMD was inconsistent.
A recent NIH study found no evidence that eating a calcium-rich diet or taking supplements increases the risk of age-related macular degeneration. The study suggests that high calcium intake may be protective, but more research is needed to confirm this finding.
Research from University of Queensland shows that heightened brain activity in the visual cortex is associated with visual hallucinations in people with macular degeneration. The findings could help reduce misdiagnosis and improve diagnosis of Charles Bonnet Syndrome.
A new study published in the Journal of the Academy of Nutrition and Dietetics found that consuming vegetable nitrates, primarily from green leafy vegetables and beetroot, can reduce the risk of early-stage age-related macular degeneration by 35%. Eating 100-142mg of vegetable nitrates daily was associated with this reduced risk.
The European MACUSTAR consortium is conducting a multi-country clinical study on early AMD, focusing on intermediate-stage disease progression. Novel tests will be developed to assess earlier stages of the disease, improving diagnosis and treatment methods.
A 15-year study found that people who eat at least one serving of oranges daily have a 60% reduced risk of developing late macular degeneration. Flavonoids in oranges appear to help prevent against the eye disease.
Research at Washington University School of Medicine found that aging immune cells contribute to inflammation and abnormal blood vessel growth in macular degeneration, potentially leading to vision loss. The study identified microRNA-150 as a potential therapeutic target for preventing progression to advanced forms of the disease.
USC Roski Eye Institute researchers develop a stem cell-based retinal implant to treat advanced dry age-related macular degeneration. The treatment shows promise in improving visual function and stopping disease progression.
A bioengineered retinal implant, composed of human embryonic stem cells, has been shown to halt vision loss in advanced non-neovascular age-related macular degeneration. The implant was well-tolerated and successfully integrated with retinal tissue, demonstrating potential for a new therapy for this progressive disease.
Researchers at UCSB developed a specially engineered retinal patch using stem cells to treat people with sudden severe sight loss from wet AMD. The study showed improvements in vision, enabling patients to read and perform daily tasks.
A recent study published in Nature Medicine has identified a critical trigger for the damaging inflammation that causes macular degeneration. The enzyme cGAS plays a key role in detecting foreign DNA and is activated in the dry form of age-related macular degeneration, leading to vision loss.
A recent study found a significant decline in the risk of age-related macular degeneration among baby boomers compared to earlier generations. The five-year risk for AMD decreased by 60 percent for each generation, with unclear reasons behind this trend.